Morgan Stanley Upgrades Axsome Therapeutics to Overweight

Summary

Morgan Stanley has initiated coverage of Axsome Therapeutics (NASDAQ: AXSM) with an ‘Overweight’ rating and a target price of $190. The firm expects AXS-05’s supplemental new drug application for Alzheimer’s disease agitation to be successful, potentially generating $900 million in sales by 2030. The ongoing rollout of Auvelity for major depressive disorder is also seen as a positive factor. Despite Axsm’s potential, analysts suggest that certain AI stocks might offer better investment opportunities.insidermonkey

Impact Analysis

This event is primarily at the company level, as it specifically affects Axsome Therapeutics through Morgan Stanley’s coverage and rating. The first-order effects include a positive impact on Axsome’s stock price due to the optimistic outlook on its drug pipeline, particularly AXS-05 and Auvelity. Second-order effects might involve increased interest in pharmaceutical stocks and confidence in companies with promising drug developments. However, the suggestion that AI stocks may offer better investment opportunities introduces an industry-level perspective, highlighting alternative sectors for investors to consider. Opportunities involve investing in Axsome Therapeutics based on the forecasted success of its products, while risks include potential competition or delays in drug approval.insidermonkey